| Autor: |
Shuai, Wen, Zuo, Zhuang, Li, Nianyi, Garces, Sofia, Jelloul, Fatima Zahra, Ok, Chi Young, Li, Shaoying, Xu, Jie, You, M. James, Wang, Wei, Rehder, Catherine, Jabbour, Elias J., Patel, Keyur P., Medeiros, L. Jeffrey, Yin, C. Cameron |
| Předmět: |
|
| Zdroj: |
Cancer (0008543X); Mar2023, Vol. 129 Issue 6, p878-889, 12p |
| Abstrakt: |
Background: ETNK1 mutation has been suggested as a useful tool to support the diagnosis of atypical chronic myeloid leukemia. ETNK1 mutations, however, occur in other myeloid neoplasms. Methods: The authors assessed the clinicopathologic and molecular genetic features of 80 ETNK1‐mutated myeloid neoplasms. Results: Thirty‐seven neoplasms (46%) were classified as myelodysplastic syndrome, 17 (21%) were classified as myelodysplastic/myeloproliferative neoplasm, 14 (18%) were classified as acute myeloid leukemia, and 12 (15%) were classified as myeloproliferative neoplasm. ETNK1 mutations were detected at the first test in 96% of patients, suggesting that ETNK1 mutation is an early event in pathogenesis. ETNK1 mutations represented the dominant clone in 63% of patients and was persistently dominant in 93%. The variant allele frequencies were usually higher in acute myeloid leukemia and increased upon leukemic transformation. ETNK1 mutation was accompanied by coexisting mutations in all patients, with ASXL1 (50%), TET2 (25%), EZH2 (24%), RUNX1 (24%), and SRSF2 (24%) mutations being the most common. Neoplasms with ETNK1 mutations were associated with morphologic dysplasia, increased blasts, myelofibrosis, and noncomplex karyotypes. With a median follow‐up of 16.5 months, 30 patients died, 44 had persistent disease, and four achieved complete remission after stem cell transplantation. Conclusions: ETNK1 mutation is present in various myeloid neoplasms, often as an early event and a dominant clone and always with concurrent mutations. It may play an important role in the pathogenesis and progression of myeloid neoplasms by causing DNA damage and inducing other mutations and genomic instability, and it may serve as a potential therapeutic target. ETNK1 mutation is not disease‐specific and should be interpreted with caution to classify myeloid neoplasms. ETNK1 mutation is not disease‐specific and is associated with dysplasia, increased blasts, myelofibrosis, and noncomplex karyotypes. ETNK1 mutation often represents an early event and a dominant clone, and it has a probable role in leukemogenesis and targeted therapy. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text